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Background: The existing metrics of malaria transmission are limited in sensitivity under low transmission intensity.
Robust surveillance systems are needed as interventions to monitor reduced transmission and prevention of rapid
reintroduction. Serological tools based on antibody responses to parasite and vector antigens are potential tools for
transmission measurements. The current study sought to evaluate antibody responses to Anopheles gambiae
salivary gland peptide (gSG6- P1), as a biomarker of human exposure to Anopheles bites, in different transmission
settings and seasons. The comparison between anti-MSP-119 IgG immune responders and non-responders allowed
exploring the robustness of the gSG6-P1 peptide as a surveillance tool in an area of decreasing malaria
transmission.
Methods: Total IgG levels to gSG6-P1 were measured in an age-stratified cohort (< 5, 5–14 and≥ 15 years) in a
total of 1,366 participants from three localities in western Kenya [Kisii (hypoendemic), Kakamega (mesoendemic),
and Kombewa (hyperendemic)] including 607 sera that were additionally tested for MSP-119 specific responses
during a low and a high malaria transmission seasons. Antibody prevalence and levels were compared between
localities with different transmission intensities. Regression analysis was performed to examine the association
between gSG6-P1 and MSP-119 seroprevalence and parasite prevalence.
Result: Seroprevalence of gSG6-P1 in the uphill population was 36% while it was 50% valley bottom (χ2 = 13.2,
df = 1, p < 0.001). Median gSG6-P1 antibody levels in the Valley bottom were twice as high as that observed in the
uphill population [4.50 vs. 2.05, p < 0.001] and showed seasonal variation. The odds of gSG6-P1 seropositives having
MSP-119 antibodies were almost three times higher than the odds of seronegatives (OR = 2.87, 95% CI [1.977,
4.176]). The observed parasite prevalence for Kisii, Kakamega and Kombewa were 4%, 19.7% and 44.6% whilst the
equivalent gSG6-P1 seroprevalence were 28%, 34% and 54%, respectively.
Conclusion: The seroprevalence of IgG to gSG6-P1 was sensitive and robust in distinguishing between hypo, meso
and hyper transmission settings and seasonal fluctuations.* Correspondence: kbadu@noguchi.mimcom.org
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Accumulating evidence indicate that malaria burden in
Africa is declining [1,2]. Several countries that previously
had high malaria burden have seen over 50% reduction
in malaria burden within the past ten years, including
Eritrea, Rwanda, Zanzibar [3], Pemba [4], Tanzania
mainland [5], Kenya [6], Gambia [7], Zambia [8], and
Swaziland [9]. Three countries, including Morocco, in
Africa were certified as malaria-free in 2011 [10]. More-
over, a longitudinal decline in the density of malaria vec-
tors was observed during an 11-year study period, in
spite of the absence of organized vector control [11].
Guerra and others have estimated that there are about 1
billion people currently living under unstable or ex-
tremely low malaria risk globally. These areas are amen-
able for malaria elimination [12]. As programmes
successfully reduce transmission to near elimination
levels, the measurement of malaria-associated morbidity
and mortality as a means of tracking reducing burden
will become difficult and insensitive. Novel approaches
to surveillance are, therefore, necessary to ensure that
once elimination has been achieved, it is not threatened
by a rapid reintroduction [13]. People living in areas of
unstable or extremely low malaria risk may lose the abil-
ity of maintaining naturally acquired immunity [14].
This presents a special challenge, i.e., the risk of possible
catastrophic rebound such as the one occurred in the
highlands of Madagascar in the 1980s where an epi-
demic killed more than 40,000 people [15]. Thus, the
quest for sensitive and robust surveillance tools has be-
come imperative. Such surveillance tools are needed as
an intervention to reduce transmission, to measure
transmission interruption and maintenance of zero
transmission; the tools should also be useful in mapping
the risk of focal residues of transmission to enable tar-
geted control. Unfortunately, the existing metrics of
malaria transmission have serious limitations when
transmission is approaching zero. The entomological
inoculation rate (EIR), the gold standard of malaria
transmission intensity (MTI) [16], becomes difficult,
expensive, and sometimes virtually impossible to meas-
ure when transmission is very low [17,18].
Serological tools based on antibody responses to para-
site and vector antigens are potentially valuable for
robust transmission measurement [19-21]. Particularly,
Merozoite Surface Protein 1 (MSP 119) seroconversion
rates have been shown to correlate with malaria trans-
mission intensity (EIR) [22,23]. MSP-119 seroprevalence
and antibody level is robust and sensitive in distinguish-
ing malaria exposures at different altitudes, age groups,
and proximity to mosquito breeding habitats in popula-
tions separated by only 5 km apart [24]. The parallel
measure of the antibody response to Anopheles salivary
antigen would be especially convenient, because it willallow for assessment of Anopheles exposure in children,
which is ethically unfeasible by human landing catches.
Moreover, serological markers of exposure to Anopheles
bites would represent a complementary tool in low mal-
aria transmission areas for the monitoring of control
interventions based on anti-vector measures [17,25].
The IgG response to whole saliva extracts of Anopheles
gambiae has been observed as a marker of exposure to
An. gambiae bite, and high anti-saliva IgG levels is a pre-
dictive indicator of malaria morbidity [26,27]. The An.
gambiae salivary gland gSG6 protein and derived P1
peptide are specific to An. gambiae and elicit specific
antibody response in the human host [28,29]. It is anti-
genic in travelers transiently exposed to Anopheles bites
in malaria endemic areas of Africa [30]. The gSG6 pro-
tein has been recently reported to have the potential to
represent a general epidemiological marker of exposure
since it shares 99% and 80% identity with Anopheles ara-
biensis and Anopheles funestus, respectively, which con-
stitutes the main Afro-tropical malaria vectorial system
[29,31]. The synthetic peptide (gSG6-P1) derived from
An. gambiae salivary recombinant protein gSG6-P1 is
reportedly highly specific to Anopheles species and im-
munogenic [21,29] and its synthetic nature guarantees
high reproducibility for the assay [21]. It is also a bio-
marker in low exposure area [28] and specific to An.
funestus bites [32]. There is as yet, lack of information
on the value of gSG6-P1 as a surveillance tool in asses-
sing the risk of exposure to malaria parasites at the
population and individual level. This study thus sought
to evaluate anti-gSG6- P1 IgG responses in PfMSP-119
responders and non-responders across different altitudes
under high, moderate and low transmission settings
across different age groups and seasons. The robustness
of the gSG6-P1 as a biomarker of parasite exposure and
the possibility of utilizing the biomarker as a surveillance
tool in an era of decreasing malaria transmission where
traditional tools become insensitive and unfeasible to
track malaria transmission is reported.
Methods
Study site
The study was conducted in three sentinel sites in west-
ern Kenya, comprising hyperendemic site of Kombewa
in Kisumu County, mesoendemic site of Iguhu in the
Kakamega County, and hypoendemic site Marani village
in the Kisii County. Iguhu and Kisii are sites in the high-
lands and Kombewa is in a lowland area of the Lake Vic-
toria basin, Figure 1.
Iguhu area (34°45’9” E, 00°10’9” N, 1,430–1,580 m
above sea level) was subdivided into two locations: an
uphill site and valley bottom site, these have been
described to have distinct malaria epidemiology
[24,33,34]. The area is characterized by mosaic land use
Figure 1 Shows the Map of the study sites.
Badu et al. Malaria Journal 2012, 11:318 Page 3 of 9
http://www.malariajournal.com/content/11/1/318types: the hill is mostly maize farms dotted by patches
of tea plantation. A slow flowing Yala River runs
through the flood prone flat valley bisecting the com-
munity and because several swamps are located along
the Yala River, mosquito larval habitats are common at
the river banks near the valley bottom. The entomo-
logical inoculation rate (EIR) at the valley was 16.6
during 2003–2004 [35], while it was 0.04 at in the up-
hill area during 1999–2000 [33]. Marani (34° 48’9” E,
00°35’9” S, 1,540–1,740 m a.s.l) in the Kisii county, is
located on the highland plateau adjacent to the Lake
Victoria Basin. Steep, gently sloping hills and undulating
topography characterizes the area. The highland area hassmall patches of forests along the rivers and streams,
which are remnants of a larger forest that has been
cleared for cultivation and pasture. The valley is charac-
terized by an efficient drainage system and floods are
not common. Marani area is under low and unstable
malaria transmission and thus has been described as
hypo endemic for malaria [36]. The mean annual rainfall
in the western Kenya highlands has been 1800–
2000 mm and the mean annual temperature has ranged
from 17 to 20°C [37] and the predominant malaria vec-
tor species is An. gambiae s.s., with insignificant propor-
tion of An. arabiensis and An. funestus [35]. Other
details of the area have been described elsewhere [34].
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is in the Kisumu County and lies in the vicinity of the
Lake Victoria basin. Kombewa is characterized by a rolling
terrain bisected by small streams with poor drainage. It is
found within the semi-arid lowland and is warmer and
drier compared to the two highland areas. Mean monthly
rainfall was 120.7 mm, mean monthly maximum and
minimum temperatures were 29.1°C and 18.4°C, respect-
ively. Here malaria is hyper-endemic with P. falciparum
accounting for more than 95% of infections. Anopheles
gambiae s.s. and An. funestus are the major vectors with
recent increased population in An. arabiensis [36]. The
EIR in recent times has been estimated to be of 31.1 infec-
tious bites per person per year [35].
Parasitological and immunological survey
Two cross-sectional surveys were conducted among age
stratified cohorts (≤5, 5–14, ≥15 years) at the Kakamega
site during the dry season (February - March) and the
rainy season (June-July) in 2009; this survey has been
fully described in a previous study [24]. Another survey
was conducted among randomly selected school-age
children (5–13 years) in all study sites from February to
April, 2011. Standard finger prick blood was collected
into microvettes (SARSTEDT Numbrecht, Germany)
containing EDTA. This was later spun and about 50μL
of plasma was aspirated and stored in -80°C until use.
Giemsa-stained blood smears were also made for the es-
timation of parasite prevalence.
Study population and demography
A total of 744 sera (322 belonged to the uphill commu-
nity whilst 422 were from the valley bottom area) avail-
able from previous study [24], were successfully tested
for IgG response to gSG6-P1; out of this number, 607
of them had known specific antibody responses to
MSP-119. Participants were categorized into three age
groups, i.e. <5 (n = 49), 5–14 (n = 153) and ≥ 15 years
(n = 120); respectively, from the uphill community.
Similarly from the valley bottom population, 79, 159
and 189 belonging to the respective age categories <5,
5–14 and ≥ 15 years were tested. Seasonally a total of
384 were sampled in the dry season whilst 360 tested
were from the rainy season. The second survey sampled
622 primary school children ages between five and 16,
among them 202 participants were from Kombewa, 203
from Iguhu, and 217 from Marani.
Salivary peptide gSG6-P1
The gSG6-P1 peptide was designed using bioinformatics
to maximize its Anopheles specificity and its immuno-
genicity, as previously described [21]. It was synthesized
and purified (>95 %) by Genepep SA (St-Jean de Vedas,
France) and shipped to Kenya in lyophilized form.Peptides were constituted in 0.23 mL ultra-filtered la-
boratory grade water and kept frozen at −80°C until use.
Measurement of anti-human IgG antibodies for gSG6-P1
antigen
Total IgG antibody against the gSG6-P1 antigen was
measured by enzyme-linked immunosorbent assay
(ELISA) technique described previously [28] with modi-
fications. Briefly, 96-well micro-assay plates (Maxisorp,
Roskilde, Denmark) were coated with gSG6-P1 antigen
at a concentration of 20 μg/mL and incubated at 37°C
for two and half hours. Plates were blocked with 0.5%
Casein containing 0.05% Tween20 for 1 hour at 22°C.
Test sera, diluted 1:20 in blocking buffer, were added
and incubated at 4°C over night. Anti-gSG6- P1 IgG
were detected with a horse radish peroxidase (HRP)-
conjugate of goat anti-human IgG antibody (Nordic Im-
munology, Tilburg, Netherlands) diluted 1:10,000 in PBS
for1 hour incubation at 22°C. A peroxidase substrate, 2,
2’-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) or
ABTS (Kirkegaard & Perry Laboratories Inc., Gaithers-
burg, MD) was added and plates incubated for 50 min-
utes at 22°C. Enzymatic reaction was stopped with 10 μl
of 20% SDS (Sigma, St. Louis, MO). Optical density
(OD) measurements were taken at 405 nm on a spectro-
photometer (SpectraMAX 340PC, Molecular Devices
Corporation, USA). Each test sample was assessed in du-
plicate wells and, in parallel, with a blank well containing
no antigen (ODn) to control for non-specific reactions
in the plasma and the reagents. IgG levels were
expressed as final OD calculated for each serum as the
mean OD value with antigen minus the OD value with-
out antigen (ODn). Intra- and inter-assay variation of
control samples was below 25%. Sera whose duplicates
showed a coefficient of variation (CV) 25% and above
were not included in the analysis. The mean OD of un-
exposed controls (from the USA, N= 30) plus 3 SD was
used as cut-off value for seropositivity. The cut off value
being 0.35.
Measurement of anti-human IgG antibodies for PfMSP119
(FVO) antigen
Total IgG antibody to PfMSP1 was measured by indirect
ELISA as previously described in our earlier studies [24].
The expression and purification of the PfMSP1 FVO re-
combinant protein has also been described [38,39]. In
brief, 96-well micro-assay plates (Maxisorp, Roskilde,
Denmark) were coated with 0.2 μg PfMSP1 FVO antigen
(diluted in phosphate buffered saline) and incubated
overnight at 4°C. After blocking, test sera were added in
triplicate wells and serially diluted from 1:50 to 1:64,000.
Plates were incubated for 2 h at 22°C and HRP conjugate
of goat antihuman IgG (KPL, Gaithersburg, MD) added.
After 1 h incubation, ABTS (Kirkegaard & Perry
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incubated for 1 h at 22°C. The enzymatic reaction was
stopped by adding 10μL of 20% SDS (Sigma, St. Louis,
MO). Plates were washed and the OD measurements
were taken at 414 nm on a spectrophotometer (Spectra-
MAX 340PC, Molecular Devices Corporation, USA). Ser-
ial dilutions were used to fit a four-parameter curve
using SoftMax Pro v5.3 (Molecular Devices). Results
were expressed in titer values, the titer endpoint being
defined in this study as the calculated serum dilution
yielding an OD of 1.0.
Data analysis
Seroprevalence was defined as the number of positive
responders to a specific antigen out of the total number
tested. Differences in the proportion of seroprevalence
of gSG6-P1 between age-stratified, uphill and valley resi-
dents were compared by the χ2 test with p < 0.05 consid-
ered statistically significant. The Mann–Whitney test
was used to test if medians of antibody levels were dif-
ferent between localities. Multinomial logistic regression
was used to examine the association between gSG6-P1
and MSP-119 seroprevalence adjusting for age in the
population. Linear regression was used to examine the
trend of parasite prevalence and age at different local-
ities ODs of gSG6-P1.All data were analysed and
graphed using GraphPad Prism software (San Diego,
CA, USA).
Scientific and ethical considerations
Scientific and ethical clearance was granted by the sci-
entific and ethical review committee of Kenya Medical
Research Institute and University of California at
Irvine. Participants were enrolled from the primary
schools in the study sites through the primary school












Figure 2 Shows Bar graphs of specific Median humoral responses to
Uphill (n = 322) and valley (n = 422) residents. Mann Whitney: P = 0.0002. B:
Whitney: P = 0.028. Error Bars show inter-quartile ranges (Lower 25 %- Uppeoffice of the Ministry of Health. Participants were
recruited into the study after their parents/guardians
gave informed consent. Prospective participants were
excluded from the study if they were unwilling to par-
ticipate; asymptomatic infections were not treated with
anti-malarial regimen in line with the standard malaria
treatment guidelines from the Ministry of Health of
Kenya, symptomatic participants were referred to the
local government hospitals or clinics for diagnosis and
treatment free of charge.Results
Specific IgG responses to gSG6-P1 in valley and uphill
communities and its association to MSP-119
seroprevalence
There were marked differences in seroprevalence as well
as IgG levels to gSG6-P1 peptide between the uphill and
valley populations which were statistically significant.
The overall seroprevalence in the uphill population was
36% and that of in the valley population was 50%
(χ2 = 13.2 p <0.001). Median antibody levels in the valley
were twice as high as that observed in the uphill popula-
tion (Mann Whitney; p < 0.001; Figure 2A). Furthermore
seasonal variation was also observed in antibody levels
(Mann Whitney; p = 0.028; Figure 2B), with higher levels
during rainy season.
The risk of seroconversion to MSP-119 specific Ab, fol-
lowing exposure to Plasmodium falciparum was always
higher for gSG6-P1 seropositives than seronegative indi-
viduals (Table 1). Altogether the odds of gSG6-P1 sero-
positives having MSP-119 Ab were almost three times
higher than the odds of seronegatives. This was signifi-
cant in the uphill population by a factor of 2.2 and
highly so in the valley population by a factor of 2.6











gSG6-P1 in different localities and seasons. A: responses between
responses between and Rainy (n = 360) Dry (n = 384) seasons. Mann
r 75 %).
Table 1 Association between gSG6-P1 and MSP-119
seroprevalence at the different localities
MSP-1 19 seroprevalence
gSG6-P1 seroprevalence
Locality (n) Odds Ratio 95% CI P value
Uphill (232) 2.168 [1.203, 3.903] 0.010
Valley (375) 2.668 [1.550, 4.592] < 0.001
Total Uphill and Valley (607) 2.873 [1.977, 4.176] < 0.001
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responses to gSG6-P1, and MSP-119
There was no correlation observed between parasite
prevalence and age in the uphill population (Figure 3A),
however there was a strong negative correlation between
the parasite prevalence and age in the valley population
(Figure 3B), and when the data was combined (Figure 3C).
Parasite prevalence was generally very low relative to sero-
prevalence of gSG6- P1 and MSP-119 at all study sites
(Figure 3). Linear regression analysis revealed significant
differences in the slopes in the uphill population (F= 5.2,
df = 2, 21, P = 0.014), Valley population (F= 4.3, df = 2, 21,
P = 0.026) and when both populations were analysed to-
gether (F= 6.5, df = 2, 48, P = 0.003). MSP-119 seropreva-
lence was strongly associated with age at individual sites
and in total (Figure 3). The correlation between gSG6-P1
specific seroprevalence and age was considerably high in
the uphill population (R2 = 0.40, Figure 3A), the contrast
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Figure 3 A scatter plot showing the trends of gSG6-P1 and MSP-119 s
locations. A (Uphill n = 232), B (valley bottom n= 375) and C (Total populain the valley population (R2 = 0.10, Figure 3B) and again
when the data was combined (R2 = 0.19, Figure 3C).
The differences in the magnitude of responses between
MSP -119 and gSG6-P1 specific antibodies, as indicated
by the differences in their intercept are highly significant
at both sites and when the data was combined (Figure 3).
However, antibody trends as depicted by the slopes did
not differ.
Specific antibody responses to gSG6-P1 across different
transmission settings and risk of parasite exposure
We observed significant differences in parasite preva-
lence and gSG6-P1 levels across different transmission
settings (Figure 4). The hypoendemic Kisii area had the
lowest parasite prevalence of barely 4% followed by the
mesoendemic area of Kakamega with 19.7%. Parasite
prevalence was highest in the hyperendemic Kombewa
area at 44.6% (χ2 = 31.0 df = 2, P < 0.001). The observed
parasite prevalence was associated with increasing
gSG6-P1specific antibody prevalence along the transmis-
sion intensity cline of Kisii (28%), Kakamega (34%) and
Kombewa (54%) (χ2 = 99.0 df = 2, P < 0.001). The two
measurements were significantly positively associated
(χ2 = 10.9, df = 2, P = 0.004).
Discussion
Marked differences in gSG6-P1 specific seroprevalence
and antibody levels were observed between the uphill
and valley bottom populations. The IgG levels of toValley
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Figure 4 A bar graph showing gSG6-P1 seroprevalence and
their respective parasite prevalence in different endemic
localities. Kisii (n = 222), Kakamega (n = 203) and Kombewa (n = 202).
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higher than observed in the uphill population, suggesting
that, the valley bottom population is exposed to higher
vector densities than the uphill population. Seasonally,
antibody levels of gSG6 P1 in the rainy season were
higher than the levels observed in the dry season; how-
ever this was not the case in the seroprevalence. It has
been previously shown that the levels of specific IgG re-
sponse to this peptide reflect recent exposure; antibody
levels tend to be higher in actively exposed individuals
with a concomitant decline in the absence of exposure
[40]. The differences in the seroprevalence and Ab levels
to gSG6-P1 may be attributed to the differences in vec-
tor densities between the two sites; majority of breeding
habitats in the hilly highlands are confined to the valley
bottoms because the hillside gradients provide efficient
drainage [41]. Githeko et al. [33] found that, the major-
ity of the adult Anopheles females [An. gambiae s.l. 98%
and An. funestus 99%], were found up to 500 m from
the breeding habitats which were clustered in the valley
bottom. Very few vectors are found at mid hill (1%) and
at the hill top (1%). It is well known that the topography
of the highlands in western Kenya play a major role in
malaria prevalence as this difference between the two
sites has been reported by other studies [33,34]. In re-
spect to this evidence it may be indicated that the
gSG6-P1 biomarker is robust and sensitive enough to
distinguish between the vector densities of exposure in
a population which is only 5 km apart.
Regression analysis revealed that, the odds of having
detectable anti-MSP-119 Ab response was significantly
higher for gSG6-P1 seropositive individuals. This implies
that, the risk of exposure to malaria parasite is higher in
individuals presenting with anti -gSG6 P1 Ab; this was
consistent both in the uphill and valley residents. With
the known differences in vector exposure between the
two sites, it is conservable to say that, higher exposureto vector results in higher risk of parasite transmission.
This conclusion is consistent with an established view of
malaria epidemiology; that the risk of receiving a mos-
quito bite as well as susceptibility to infection are highly
heterogeneous and that 20% of people receive 80% of all
bites and infections [42,43].
Indeed it was exactly the case when we compared anti
-gSG6-P1 IgG responses in school children from three dif-
ferent malaria transmission intensity zones. Marani, Kaka-
mega and Kombewa, where their respective EIR are as
follows: 0.4, 16.6 and 31.1 [35]. In the same order we
observed parasite rates of 4%, 19.7% and 44.6%. The
observed gSG6-P1 seroprevalence significantly declined
with level of endemicity (Kombewa (54%), Kakamega
(34.1%) and Marani (28.1%) which paralleled the parasites
rates (Figure 4). However the gSG6-P1 seroprevalence
rates relatively higher being indicative of higher sensitivity.
At the population level, we have observed that gSG6-P1
seroprevalence may correlate with the risk of pathogen
transmission, in agreement with previous results showing
that high anti-saliva IgG levels were predictive indicators
of malaria morbidity [26]. Anti-Anopheles dirus salivary
proteins Ab occurred also predominantly in patients with
acute P. falciparum or Plasmodium vivax malaria com-
pared to individuals from non-endemic areas [27]. In
South Americas, the presence of anti-Anopheles saliva Ab
has been described in malaria-endemic areas. Adult
volunteers from communities in the state of Rondônia,
Brazil, were tested for Ab response against Anopheles dar-
lingi salivary gland sonicates (SGS). Individuals infected
with P. vivax presented higher levels of anti-SGS Ab than
did non-infected individuals. This potential biomarker
appeared thus useful as an epidemiological tool for dis-
criminating between infected and non-infected individuals
with a high likelihood ratio [44].
As expected, MSP-119 seroprevalence was strongly
associated with age at individual sites and in general.
The longevity and the cumulative nature of anti-MSP-
119 Ab responses is well known. However the age trends
observed for gSG6-P1 responses in the same cohort was
intriguing. The overall correlation between anti- gSG6-
P1 Ab seroprevalence and age was very weak, particu-
larly so in the valley bottom population, however these
trends were considerable in the uphill population
(Figure 3). The lack of correlation in the age trends of
gSG6-P1seroprevalence in the overall data as well as the
valley bottom residents in comparison to MSP-119 may
be informative that anti - gSG6-P1 Ab is not cumulative.
It is noteworthy that age trends of gSG6-P1is influenced
by the differences in the transmission intensity. In
hyperendemic areas of Burkina Faso, Rizzo and others
found that children had higher responses to whole saliv-
ary gSG6 proteins while adults had diminished Ab
responses, suggesting desensitization of the immune
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confirms the non cumulative nature of Ab response
gSG6-P1 peptide and thus its robustness in measuring
transient exposure (or seasonal) in a hypoendemic popu-
lation as observed in our uphill residents and not only
restricted to children in hyperendemic areas. It will add
to the advantages of gSG6-P1 as it will be more useful
even under low malaria transmission period as envisaged
in the pre elimination and elimination phase of malaria.
MSP-119 Ab responses appeared largely higher than
anti- gSG6-P1 responses in terms of Ab level. The differ-
ences further lends credence to the observation that
MSP1 is cumulative or perhaps more immunogenic than
gSG6-P1. Furthermore, the amount of gSG6 proteins
injected in the blood as well as the time of contact with
immuno-competent cells is relatively shorter than
MSP119 which is a blood stage antigen and multiples
severally during the erythrocytic cycle of the parasite.
The gSG6-P1 is a synthetic peptide specially designed
to enhance its sensitivity and immunogenicity [21], and
it has reportedly been very sensitive [25,28] and highly
immunogenic developing immune responses even in tra-
velers only transiently exposed to mosquito bites.Conclusion
gSG6 P1 seroprevalence correlates with parasite preva-
lence at the population level. The seroprevalence of
gSG6-P1 was sensitive and robust to distinguish between
hypo, meso and hyper transmission settings and the level
of specific Ab distinguished between seasonal fluctua-
tions. The gSG6 P1 seroprevalence may be exploited as
an epidemiological marker of risk of parasite transmis-
sion and a vector surveillance tool across different popu-
lations and malaria transmission settings.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
KB carried out the field survey, the serological experiments, and the
serological analysis and wrote the first draft of the manuscript. JS and FR
supervised laboratory procedures and assay development; GZ supported
data analysis. KB, GY, BWL and, AG conceived the study, participated in its
design and implementation and JL, FR and JMO contributed to data analysis
and manuscript development. YA coordinated the collection of samples. All
authors read and approved the final manuscript.Acknowledgements
We thank Sally Mongoi for efficient management of field operations, Paul
Osodo, Caroline Okoth and Esther Bosire for the hard work in sample
collection. We thank Evalina Angov for providing the MSP-119 plate antigen.
Special appreciation goes to Ming Chie Lee for developing the map of the
study area. We appreciate all study participants and the staff at the Iguhu
district government hospital as participants from other communities. This
manuscript is published under the permission of the Director of Kenya
Medical Research Institute.Grants provided by the National Institute of Health
(D43 TW001505 and R01 A1050243).Author details
1Department of Theoretical and Applied Biology, College of Sciences, Kwame
Nkrumah, University of Science & Technology, Kumasi, Ghana. 2Center for
Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
3Walter Reed Project, United States Army Medical Research Unit-Kenya,
Kisumu. 4Institute of Research for Development (IRD), MIVEGEC unit -
(IRD224-UM1-UM2-CNRS 5290), Cotonou, Benin. 5Program in Public Health,
College of Health Sciences, University of California at Irvine, Irvine, CA 92697,
USA.
Received: 22 June 2012 Accepted: 6 September 2012
Published: 10 September 2012References
1. Rodrigues A, Schellenberg JA, Kofoed PE, Aaby P, Greenwood B: Changing
pattern of malaria in Bissau, Guinea Bissau. Trop Med Int Health 2008,
13:410–417.
2. O'Meara WP, Mangeni JN, Steketee R, Greenwood B: Changes in the
burden of malaria in sub-Saharan Africa. Lancet Infect Dis 2010,
10:545–555.
3. World Health Organization: WHO World Malaria Report. Geneva, Switzerland;
2009.
4. Jaenisch T, Sullivan DJ, Dutta A, Deb S, Ramsan M, Othman MK, Gaczkowski
R, Tielsch J, Sazawal S: Malaria incidence and prevalence on Pemba Island
before the onset of the successful control intervention on the Zanzibar
archipelago. Malar J 2010, 9:32.
5. Mmbando BP, Vestergaard LS, Kitua AY, Lemnge MM, Theander TG, Lusingu
JP: A progressive declining in the burden of malaria in north-eastern
Tanzania. Malar J 2010, 9:216.
6. O'Meara WP, Bejon P, Mwangi TW, Okiro EA, Peshu N, Snow RW, Marsh K:
Effect of a fall in malaria transmission on morbidity and mortality in
Kilifi, Kenya. Lancet 2008, 372:1555–1562.
7. Ceesay SJ, Casals-Pascual C, Erskine J, Anya SE, Duah NO, Fulford AJC, Sesay
SSS, Abubakar I, Dunyo S, Sey O, Palmer A, Fofana M, Corrah T, Bojang KA,
Whittle HC, Greenwood BM, Conway DJ: Changes in malaria indices
between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet
2008, 372:1545–1554.
8. Chizema-Kawesha E, Miller JM, Steketee RW, Mukonka VM, Mukuka C,
Mohamed AD, Miti SK, Campbell CC: Scaling up malaria control in
Zambia: progress and impact 2005–2008. Am J Trop Med Hyg 2010,
83:480–488.
9. Kunene S, Phillips AA, Gosling RD, Kandula D, Novotny JM: A national
policy for malaria elimination in Swaziland: a first for sub-Saharan Africa.
Malar J 2011, 10:313.
10. World Health Organization: WHO World Malaria Report. Geneva, Switzerland;
2011.
11. Meyrowitsch DW, Pedersen EM, Alifrangis M, Scheike TH, Malecela MN,
Magesa SM, Derua YA, Rwegoshora RT, Michael E, Simonsen PE: Is the
current decline in malaria burden in sub-Saharan Africa due to a
decrease in vector population? Malar J 2011, 10:188.
12. Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, Hay SI, Snow RW:
The limits and intensity of Plasmodium falciparum transmission:
Implications for malaria control and elimination worldwide. PLoS Med
2008, 5:e38.
13. Greenwood BM: Control to elimination: Implication for malaria research.
Trends Parasitol 2008, 24:449–454.
14. Doolan DL, Dobaño C, Baird JK: Acquired Immunity to Malaria. Clin
Microbiol Rev 2009, 22:13–36.
15. Romi R, Razaiarimanga MC, Raharimanga R, Rakotondraibe EM, Ranaivo LH,
Pietra V, Raveloson A, Majori G: Impact of the malaria control campaign
(1993–1998) in the highlands of Madagascar: parasitological and
entomological data. Am J Trop Med Hyg 2002, 66:2–6.
16. MacDonald G: The epidemiology and control of malaria. London: Oxford
University Press; 1957.
17. The malERA Consultative Group on Monitoring, Evaluation, and Surveillance:
A research agenda for malaria eradication: monitoring, evaluation, and
surveillance. PLoS Med 2011, 8: doi:e1000400.
18. Smith T, Killeen G, Lengeler C, Tanner M: Relationships between the
outcome of Plasmodium falciparum infection and the intensity of
transmission in Africa. Am J Trop Med Hyg 2004, 71:80–86.
Badu et al. Malaria Journal 2012, 11:318 Page 9 of 9
http://www.malariajournal.com/content/11/1/31819. Bousema T, Youssef RM, Cook J, Cox J, Alegana VA, Amran J, Noor AM,
Snow RW, Drakeley C: Serologic markers for detecting malaria in areas of
low endemicity, Somalia, 2008. Emerg Infect Dis 2010, 16:392–399.
20. Cook J, Reid H, Lavro J, Kuwahata, Taleo G, Clements A, McCarthy J, Vallely
A, Drakeley C: Using serological measures to monitor changes in malaria
transmission in Vanuatu. Malar J 2010, 9:169.
21. Poinsignon A, Cornelie S, Mestres-Simon M, Lanfrancotti A, Rossignol M,
Boulanger D, Cisse B, Sokhna C, Arcà B, Simondon F, Remoue F: Novel
peptide marker corresponding to salivary protein gSG6 potentially
identifies exposure to Anopheles bites. PLoS One 2008, 3:e2472.
22. Corran P, Coleman P, Riley E, Drakeley C: Serology: a robust indicator of
malaria transmission intensity? Trends Parasitol 2007, 23:575–582.
23. Drakeley CJ, Corran PH, Coleman PG, Tongren JE, McDonald SL, Malima R,
Lusingu J, Manjurano A, Nkya WMM, Lemnge MM, Cox J, Reyburn H, Riley
EM: Estimating medium- and long-term trends in malaria transmission
by using serological markers of malaria exposure. Proc Natl Acad Sci U S A
2005, 102:5108–5113.
24. Badu K, Afrane YA, Larbi J, Stewart VN, Waitumbi J, Angov E, Ong’echa JM,
Perkins DJ, Zhou G, Githeko A, Yan G: Marked variation in MSP-119
antibody responses to malaria in western Kenyan highlands. BMC Infect
Dis 2012, 12:50.
25. Drame PM, Poinsignon A, Besnard P, Cornelie S, Le Mire J, Toto JC,
Foumane V, Dos-Santos MA, Sembène M, Fortes F, Simondon F, Carnevale
P, Remoue F: Human antibody responses to the Anopheles salivary
gSG6-P1 peptide: a novel tool for evaluating the efficacy of ITNs in
malaria vector control. PLoS One 2010, 5:e15596.
26. Remoue F, Cisse B, Ba F, Sokhna C, Herve JP, Boulanger D, Simondon F:
Evaluation of the antibody response to Anopheles salivary antigens as a
potential marker of risk of malaria. Trans R Soc Trop Med Hyg 2006,
100:363–370.
27. Waitayakul A, Somsri S, Sattabongkot J, Looareesuwan S, Cui L,
Udomsangpetch R: Natural human humoral response to salivary gland
proteins of Anopheles mosquitoes in Thailand. Acta Trop 2006, 98:66–73.
28. Poinsignon A, Cornelie S, Ba F, Boulanger D, Sow C, Rossignol M, Sokhna C,
Cisse B, Simondon F, Remoue F: Human IgG response to a salivary
peptide, gSG6-P1, as a new immuno-epidemiological tool for evaluating
low-level exposure to Anopheles bites. Malar J 2009, 8:198.
29. Rizzo C, Ronca R, Fiorentino G, Verra F, Mangano V, Poinsignon A, Sirima SB,
Nèbiè I, Lombardo F, Remoue F, Coluzzi M, Petrarca V, Modiano D, Arcà B:
Humoral response to the Anopheles gambiae salivary protein gSG6: A
serological indicator of exposure to Afrotropical malaria vectors. PLoS One
2011, 6:e17980.
30. Orlandi-Pradines E, Almeras L, Denis de Senneville L, Barbe S, Remoué F,
Villard C, Cornelie S, Penhoat K, Pascual A, Bourgouin C, Fontenille D,
Bonnet J, Corre-Catelin N, Reiter P, Pagés F, Laffite D, Boulanger D,
Simondon F, Pradines B, Fusaï T, Rogier C: Antibody response against
saliva antigens of Anopheles gambiae and Aedes aegypti in travellers in
tropical Africa. Microbes Infect 2007, 9:1454–1462.
31. Coluzzi M: Advances in the study of Afrotropical malaria vectors.
Parassitologia 1993, 35:23–29. Suppl.
32. Poinsignon A, Samb B, Doucoure S, Drame PM, Sarr JB, Sow C, Cornelie S,
Maiga S, Thiam C, Rogerie F, Guindo S, Hermann E, Simondon F, Dia I,
Riveau G, Konate L, Remoue F: First attempt to validate the gSG6-P1
salivary peptide as an immuno-epidemiological tool for evaluating
human exposure to Anopheles funestus bites. Trop Med Int Health 2010,
15:1198–1203.
33. Githeko AK, Ayisi JM, Odada PK, Atieli FK, Ndenga BA, Githure JI, Yan G:
Topography and malaria transmission heterogeneity in western Kenya
highlands: prospects for focal vector control. Malar J 2006, 5:107.
34. Munyekenye OG, Githeko AK, Zhou G, Mushinzimana E, Minakawa N, Yan G:
Plasmodium falciparum spatial analysis, Western Kenya highlands. Emerg
Infect Dis 2005, 11:1571–1577.
35. Ndenga B, Githeko AK, Omukunda E, Munyekenye G, Atieli H, Wamae P,
Mbogo C, Minakawa N, Zhou G, Yan G: Population dynamics of malaria
vectors in western Kenya highlands. J Med Entomol 2006, 43:200–206.
36. Zhou G, Afrane YA, Vardo-Zalik AM, Atieli H, Zhong D, Wamae P, Yousif EH,
Minakawa N, Githeko AK, Yan G: Changing Patterns of Malaria
Epidemiology between 2002 and 2010 in Western Kenya: The Fall and
Rise of Malaria. PLoS One 2011, 6:e20318.37. Lalah JO, Muendo BM, Getenga ZM: The dissipation of hexazinone in
tropical soils under semi-controlled field conditions in Kenya.
J Environmental Sci Health: Part B 2009, 44:690–696.
38. Burghaus PA, Holder AA: Expression of the 19-kilodalton carboxy-terminal
fragment of the Plasmodium falciparum merozoite surface protein-1 in
Escherichia coli as a correctly folded protein. Mol Biochem Parasitol 1994,
64:165–169.
39. Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, Hitt SL,
McBride JS, Diggs CL, Holder AA, Long CA, Barnwell JW, Lyon JA: The
clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of
Plasmodium falciparum strain FVO expressed in Escherichia col protects
Aotus nancymai against challenge with homologous erythrocytic-stage
parasites. Infect Immun 2005, 73:287–297.
40. Drakeley C, Cook J: Potential contribution of sero-epidemiological
analysis for monitoring malaria control and elimination: historical and
current perspectives. In Advances in Parasitology 69. Edited by David R,
Simon Iain H. Burlington: Academic; 2009:299.
41. Minakawa N, Sonye G, Mogi M, Yan G: Habitat characteristics of
Anopheles gambiae s. s. larvae in a Kenyan highland. Med Vet Entomol
2004, 18:301–305.
42. Dye C, Hasibeder G: Population dynamics of mosquito-borne disease:
effects of flies which bite some people more frequently than others.
Trans R Soc Trop Med Hyg 1986, 80:69–77.
43. Smith DL, Dushoff J, Snow RW, Hay SI: The entomological inoculation rate
and Plasmodium falciparum infection in African children. Nature 2005,
438:492–495.
44. Andrade BB, Rocha BC, Reis-Filho A, Camargo LM, Tadei WP, Mo-reira LA,
Barral A, Barral-Netto M: Anti-Anopheles darlingi saliva antibodies as
marker of Plasmodium vivax infection and clinical immunity in the
Brazilian Amazon. Malar J 2009, 8:121.
doi:10.1186/1475-2875-11-318
Cite this article as: Badu et al.: Variation in exposure to Anopheles
gambiae salivary gland peptide (gSG6-P1) across different malaria
transmission settings in the western Kenya highlands. Malaria Journal
2012 11:318.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
